The Ovarian Cancer Research Program (OCRP) housed within the Department of Defense is the federal government’s only program dedicated entirely to ovarian cancer research. Yet, funding for it is in serious jeopardy of being slashed by more than two-thirds.
Though the House passed legislation funding the OCRP at $35 million for FY2021 appropriations, the Senate has proposed a drastic reduction in funding to just $10 million. The December 18 deadline for Congress’s approval of the FY2021 budget is fast approaching, meaning the Senate and House will have to come to an agreement or else funding for all programs will expire.
Ovarian cancer advocates were instrumental last year in significantly increasing funding for OCRP from $20 million to $35 million. YOUR voice made this meaningful victory happen. This same level of support is essential for the continued success of this program in improving prevention, early diagnosis, treatment, and survival rates from ovarian cancer.
Congress must maintain the funding level of $35 million in final FY2021 appropriations. This is where you come in!
Interested in being involved with OCRA advocacy all year long? We are now accepting applications for our 2021 Advocate Leaders program. Apply today!